Genotyping Assay Market is expected to Grow Owing to the Increasing Concerns Towards Healthcare Development

Genotyping Assay
  • Genotyping Assay Market

TheGlobal Genotyping Assay Marketaccounted for USD USD 12.1 Billion billion in 2021.

Genotyping is the technology that examines micro-level genetic differences that lead to major changes in phenotype. The physical differences that make humans unique and pathological changes underlying disease is the important criteria for genotyping assay. It has a vast range of uses across basic scientific research, medicine, and agriculture. Genotyping determines differences in genetic compliment by comparing a DNA sequence to that of another sample or a reference sequence. It identifies small variations in genetic sequence within populations, such as single-nucleotide polymorphisms (SNPs).

Genotyping is a rapid, high-throughput, and low-cost alternative for screening positive COVID samples. It is designed for single-nucleotide polymorphisms (SNP) identification pipeline to identify genetic variation using sequenced COVID samples. Thus, Genotyping Assay Market proved to be quite helpful during the pandemic. Tracking genetic variations from positive CoV-2 samples yields crucial information about the number of variants circulating in an outbreak and the possible lines of transmission but sequencing every positive CoV-2 sample would be prohibitively costly for population-scale test and trace operations.

Major players of the Genotyping Assay Market such as Illumina, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Bioline, Qiagen, Danaher, F. Hoffmann-La Roche Ltd., General Electric, Sequenom, Fluidigm, Biogeniq Inc., Envigo, Helix, LGC Biosearch Technologies.

The market for genotyping assay is majorly driven by the factors such as technological advancements decreasing prices of DNA sequencing increasing incidence of genetic diseases and rising awareness of personalized medicine. Enormous advances in genotyping technology, including chips that accommodate in excess of 1 million SNP assays. In addition, the cost per genotype has been driven down to levels unimagined only a few years ago. These developments have resulted in an explosion of positive whole-genome association studies and the identification of many new genes for common diseases. Another factor that is driving the growth of the market is the rising number of new diseases globally. To examine them genotyping assay has proven to be the best solution in recent years.

North America is expected to have substantial growth in the estimated time period. Growing healthcare institutions and R&D facilities for genetic research is the key reason for the growth of Genotyping Assay Market to flourish in this region. Additionally, the region contains the world’s best R&D facilities and hospitals for treating patients. These are few of the reasons North America is expected to grow in the coming years. In North America Agilent Technologies, Thermo Fisher Scientific, and Illumina are the prominent players in the Genotyping Assay Market.

In May 2018, Agilent technologies opened a new logistics center in Texas to increase its capacity for house inventory and to fulfill the growing demand for NGS products from its genomics group.